Drugs / LBVD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05457946 | Jul 2018 → Feb 2019 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | LG Chem | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBVD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05457946 ↗ |
| Modality | Vaccine | “LBVD (Hexavalent vaccine)” NCT05457946 ↗ |
| Route | Intramuscular | “Injection within the muscle into the front area of the thigh” NCT05457946 ↗ |